Adjuvant for cancer immunotherapy

Details Adjuvant for cancer immunotherapy Adjuvant for cancer immunotherapy

1989-01-30

1993-10-19

Lee, Lester L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

424 851, 530350, 530351, A61K 3702

Patent

active

052545342

ABSTRACT:
An adjuvant for cancer immunotherapy with an immuno-activating agent, which comprises a colony stimulating factor as an active ingredient, can remarkably increase the antitumor effect of said immunoactivating agent.

REFERENCES:
patent: 4789658 (1988-12-01), Yoshimoto et al.
patent: 4847325 (1989-07-01), Shadle et al.
patent: 4863902 (1989-09-01), Amagase et al.
patent: 4963354 (1990-10-01), Shepard et al.
patent: 5104650 (1992-04-01), Ralph et al.
Ladner, M. et al., The EMBO Journal, 6 (9): 2693-2698, 1987.
Kawasaki, E., et al., Science, 230: 291-296, Oct. 1985.
Ralph, P., et al., Cellular Immunology, 76: 10-21 (1983).

Affiliated with

Also associated with

Rating

Adjuvant for cancer immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Adjuvant for cancer immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adjuvant for cancer immunotherapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1351684